Reuters Health Report

Click to View in Browser 12/25/2013 The painful path to Obamacare deadline WASHINGTON (Reuters) - Tuesday is a moment of truth for Obamacare. When it comes to walking, more is better NEW YORK (Reuters Health) - People who walk enough to meet or exceed physical activity recommendations may be less likely to die early than those who only walk a little, new research shows. Many with diabetes unaware of vision loss NEW YORK (Reuters Health) - Less than half of people with diabetes-related eye disease have been told about it, which means they're also missing out on treatment that could save their sight, U.S. researchers say. Behavioral therapy may treat migraines in kids, teens NEW YORK (Reuters Health) - Children and teens with chronic migraines may find headache relief when they pair medication with psychotherapy, according to a new study. Borderline high blood pressure tied to deaths NEW YORK (Reuters Health) - Blood pressure readings above the ideal but below the formal definition of "high" still raise a person's risk of death from stroke and heart disease and should be addressed, according to a new study. Weight loss surgery safe, beneficial: study NEW YORK (Reuters Health) - Bariatric surgery results in substantial weight loss and can turn back some diseases related to obesity, a new study finds. FDA rejects Actavis' contraceptive patch, seeks more data (Reuters) - Actavis Plc said U.S. health regulators denied approval to its contraceptive patch for women and asked for more data. Settlement reached over deadly U.S. meningitis outbreak (Reuters) - Owners and insurers of a now-bankrupt Massachusetts pharmacy linked to a deadly meningitis outbreak have agreed to pay more than $100 million to compensate victims, families of victims and creditors. Amid Obamacare late rush, government says 'don't worry' WASHINGTON (Reuters) - The U.S. government said it was still processing thousands of sign-ups for health insurance under President Barack Obama's signature healthcare law on Tuesday as Americans made a final rush to obtain medical coverage in time for New Year's Day. U.S. FDA approves Novo Nordisk's drug for rare blood clotting disorder (Reuters) - The U.S. Food and Drug Administration said on Monday it has approved Novo Nordisk's drug Tretten to prevent bleeding in patients with a rare blood clotting disorder. Related Video Feisty from birth: Saltwater crocodile just wants to fight Future repellents mess with mosquito's mind The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today   A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today   » MORE NEWSLETTERS

- 3 Times Square New York, NY 10036 USA © Copyright 2010 Thomson Reuters Ensure delivery of Reuters Newsmails, add mail@nl.reuters.com to your address book. Details Subscribe to other Reuters newsletters. Unsubscribe from this newsletter. Follow us on Twitter Friend us on Facebook Forward to a friend